Actis to acquire RX Propellant for $200m.

Actis, a global investor in sustainable infrastructure, agreed to acquire RX Propellant, a platform focused on providing real estate solutions to tenants in the life sciences and related sectors in India, for $200m. "Life sciences corporations have unique requirements and often need customised real estate solutions which are deficient in supply. The Rx Propellant management team, with over a decade-long domain experience, looks to fill this gap, and help support India-bound drug discovery and manufacturing programs by providing customised real estate solutions," Ashish Singh, Actis Partner and Head of India and SE Asia Real Estate.